The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden...

Full description

Bibliographic Details
Main Authors: Marianne G. Pouwer, Elsbet J. Pieterman, Lars Verschuren, Martien P. M. Caspers, Cornelis Kluft, Ricardo A. Garcia, Jurjan Aman, J. Wouter Jukema, Hans M. G. Princen
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
atherosclerosis
animal model cardiovascular disease
lipids and lipoprotein metabolism
coagulation/thrombosis
cholesterol
chronic myeloid leukemia
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2018.00055/full

Internet

https://www.frontiersin.org/article/10.3389/fcvm.2018.00055/full

Similar Items